## TABLE 1 TO § 100.3(a)—VACCINE INJURY TABLE—Continued

Vaccine	Illness, disability, injury or condition covered	Time period for first symptom or manifestation of onset or of significant aggravation after vaccine administration
IV. Vaccines containing rubella virus (e.g., MMR, MMRV).	A. Chronic arthritis	7–42 days (not less than 7 days and not more than 42 days).
V. Vaccines containing measles virus (e.g., MMR, MM, MMRV).	A. Thrombocytopenic purpura	7–30 days (not less than 7 days and not more than 30 days).
	B. Vaccine-Strain Measles Viral Disease in an immunodeficient recipient.	
	—Vaccine-strain virus identified	Not applicable.
	—If strain determination is not done or if lab- oratory testing is inconclusive.	≤12 months.
VI. Vaccines containing polio live virus (OPV)	A. Paralytic Polio.	
	—in a non-immunodeficient recipient	≤30 days.
	—in an immunodeficient recipient—in a vaccine associated community case	≤6 months. Not applicable.
	B. Vaccine-Strain Polio Viral Infection	Пот арріїсавіе.
	—in a non-immunodeficient recipient	≤30 days.
	—in an immunodeficient recipient	≤6 months.
	—in a vaccine associated community case	Not applicable.
VII. Vaccines containing polio inactivated virus (e.g., IPV).	A. Anaphylaxis	≤4 hours.
VIII. Hepatitis B vaccines	A. Anaphylaxis	≤4 hours.
IX. Haemophilus influenzae type b (Hib) vaccines.	No Condition Specified	Not applicable.
X. Varicella vaccines	A. Anaphylaxis	≤4 hours.
	B. Disseminated varicella vaccine-strain viral disease.	
	—Vaccine-strain virus identified	Not applicable.
	—If strain determination is not done or if lab-	7–42 days (not less than 7 days and not more
	oratory testing is inconclusive.	than 42 days).
	C. Varicella vaccine-strain viral reactivation	Not applicable.
XI. Rotavirus vaccines	A. Intussusception	1–21 days (not less than 1 day and not more than 21 days).
XII. Pneumococcal conjugate vaccines	No Condition Specified	Not applicable.
XIII. Hepatitis A vaccines	No Condition Specified	Not applicable.
XIV. Seasonal influenza vaccines	A. Anaphylaxis	≤4 hours.
	B. Guillain-Barrè Syndrome	3–42 days (not less than 3 days and not more than 42 days).
XV. Meningococcal vaccines	A. Anaphylaxis	≤4 hours.
XVI. Human papillomavirus (HPV) vaccines	A. Anaphylaxis	≤4 hours.

[FR Doc. 2020–15673 Filed 7–16–20; 4:15 pm]
BILLING CODE 4165–15–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

42 CFR Parts 409, 414, 424, and 484

[CMS-1730-P]

RIN 0938-AU-06

Medicare and Medicaid Programs; CY 2021 Home Health Prospective Payment System Rate Update; Home Health Quality Reporting Requirements; and Home Infusion Therapy Services Requirements

Correction

In proposed rule document 2020– 13792 beginning on page 39408 in the issue of Tuesday, June 30, 2020, make the following correction:

On page 39408, in the first column, in the **DATES** section, "August 31, 2020" should read "August 24, 2020".

[FR Doc. C1–2020–13792 Filed 7–17–20; 8:45 am] BILLING CODE 1301–00–D